Vical (VICL +13%) is firmer after announcing successful tests using a combination of its...

|About: Vical Incorporated (VICL)|By:, SA News Editor

Vical (VICL +13%) is firmer after announcing successful tests using a combination of its Allovectin immunotherapy with an anti-CTLA-4 antibody on animal tumors.